Hepatic disorders associated with the use of Ivermectin for SARS-CoV-2 infection in adults: a pharmacovigilance study in VigiBase
Gastroenterology and Hepatology from Bed to Bench,
Vol. 15 No. 4 (2022),
3 October 2022
https://doi.org/10.22037/ghfbb.v15i4.2383
Abstract
Aim: The aim of the present study was to review in VigiBase the reports of serious hepatic disorders associated with the use of ivermectin for COVID-19 in adults.
Background: In the face of the global health emergency caused by SARS-CoV-2, ivermectin, among other drugs, has been repurposed in some Latin American countries to treat COVID-19. Studies are needed on the safety of ivermectin for this new indication. VigiBase is the WHO pharmacovigilance database that registers all individual case safety reports (ICSRs) from more than 130 countries.
Methods: We extracted the ICSRs of men or women aged ≥ 18 years and dated between 1 January 2020 and 7 March 2021 which included an association with the use of ivermectin.
Results: Of 1393 ICSRs associated with ivermectin, 60 (4.3%) were registered as "serious." Ivermectin had been used for COVID-19 in 25 of those cases. Among the latter, 6 experienced hepatic disorders (hepatitis, hepatocellular injury, cholestasis, increased alanine aminotransferase and/or aspartate aminotransferase levels, abnormal liver function tests).
Conclusion: The safety of the use of ivermectin should be studied more exhaustively, especially as regards the possibility of hepatic disorders developing when the drug is used for COVID-19.
- Ivermectin; COVID-19; drug-induced liver injury; elevated liver function tests; hepatic dysfunction; SARS-CoV-2
How to Cite
References
Ruckmani A, Ilamathi K, Kumar Ra, Kumar PMu. COVID-19: a review of clinical trials and repurposed drugs. Int J Nutr Pharmacol Neurol Dis 2021;11:27-40.
Õmura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008;31:91–8.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:104787.
Heimfarth L, Santos VS, Araújo AA de S, Quintans-Júnior LJ, Martins-Filho PR. Ivermectin: Panacea or true promise for COVID-19. EXCLI J 2020;19:1517–9.
Mega ER. Latin America’s embrace of an unproven COVID treatment is hindering drug trials. Nature 2020;586:481–2.
Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis. J Pharm Pharm Sci 2020;23:462–9.
Kow CS, Merchant HA, Mustafa ZU, Hasan SS. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Reports 2021;73:1473-1479.
Navarro M, Camprubí D, Requena-Méndez A, Buonfrate D, Giorli G, Kamgno J, et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother 2020;75:827–34.
Gabrielli A-F, Montresor A, Chitsulo L, Engels D, Savioli L. Preventive chemotherapy in human helminthiasis: theoretical and operational aspects. Trans R Soc Trop Med Hyg 2011;105:683–93.
Veit O, Beck B, Steuerwald M, Hatz C. First case of ivermectin-induced severe hepatitis. Trans R Soc Trop Med Hyg 2006;100:795–7.
Hirota M, Toda T, Morisawa H, Mineshita S. A case report of ivermectin-induced prolonged liver dysfunction in an elderly patient with scabies. Rinsho Yakuri/Japanese J Clin Pharmacol Ther 2011;42:341–3.
The Council for International Organizations of Medical Sciences (CIOMS) (2001). CIOMS current challenges in pharmacovigilance: pragmatic approaches. Report of CIOMS working group V. https://cioms.ch/wp-content/uploads/2017/01/Group5_Pharmacovigilance.p n.d.
Biour M, Ben Salem C, Chazouillères O, Grangé J-D, Serfati L, Poupon R. Hépatotoxicité des médicaments 14e mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroentérologie Clin Biol 2004;28:720–59.
Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, Tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002;42:1122–33.
GabAllh M, El-mashad A, Amin A, Darweish M. Pathological studies on effects of ivermectin on male and female rabbits. Benha Vet Med J 2017;32:104–12.
Li Y, Cai H, Rajabalee N, Au X, Friedenberg F, Wallach S. S1027 Hepatotoxicity of remdesivir for COVID-19: systematic review and meta-analysis. Am J Gastroenterol 2020;115:S523.
Aleem A, Mahadevaiah G, Shariff N, Kothadia JP. Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. Baylor Univ Med Cent Proc 2021;34:473-477.
Montastruc F, Thuriot S, Durrieu G. Hepatic disorders with the use of remdesivir for coronavirus 2019. Clin Gastroenterol Hepatol 2020;18:2835–6.
Hanafy AS, Abd-Elsalam S. Challenges in COVID-19 drug treatment in patients with advanced liver diseases: a hepatology perspective. World J Gastroenterol 2020;26:7272–86.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806–15.
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: abnormal liver function tests. J Hepatol 2020;73:566–74.
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 2015;17:14.
- Abstract Viewed: 50 times
- PDF Downloaded: 34 times